Mutation of kinases is responsible for cellular abnormalities leading to cancer initiation, progression or metastasis.4 Single and multiple kinase inhibitors are now considered as targeted therapeutic strategies for human malignancy treatment.5 Current drug discovery research shows that PIK3CA, BRAF, VEGR and epidermal growth factor receptor (EGFR) are key oncogenic kinase drug targets.5–8. This evidence concerns the gene BRAF and cancer.